Abstract: Acute myeloid leukemia (AML) is the most common haematological malignancy in adults, and its wide range of genomic changes and molecular mutations provide potential targets for drug development. However, targeted therapeutic agents and immunotherapy cannot replace the traditional "3 + 7" regimen. About 30%-40% of newly diagnosed AML patients are primary resistant to traditional regimens, resulting in extremely poor prognosis. Relapse and refractory after induction chemotherapy are still challenges for curing AML. Methyltransferase-like 3 (METTL3), as an important methyltransferase, is important in regulating the development of AML. This article reviews the role of METTL3 in AML development and drug resistance, as well as its potential in anti-leukemia, with the aim of providing new ideas and potential therapeutic targets for overcoming drug resistance and relapse in AML.